Why Keryx Shares Skyrocketed
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biotechnology company Keryx Biopharmaceuticals soared 22% today after announcing successful results from a phase 2 study of Zerenex, its treatment to manage serum phosphorus and iron deficiency anemia in chronic kidney-disease patients who aren't dependent on dialysis, also known as NDD-CKD.
So what: If approved, Zerenex would be the first oral iron treatment to effectively treat the indication, so the positive results represent one step closer to a possible first-mover advantage. In fact, Keryx estimates that the NDD-CKD patient population stands at more than 1.3 million in the U.S. alone, giving analysts plenty of good vibes over Zerenex's blockbuster potential
Now what: Keryx now plans to meet with the Food and Drug Administration to discuss the data.
"Simply put, the data presented today demonstrate that Zerenex, an oral iron drug that increases iron stores and mitigates the need for IV iron and ESAs, has the potential to change the treatment paradigm for iron deficiency anemia in CKD," co-chairman of the study Dr. Steve Fishbane said. "An oral drug producing these results suggests the potential for a more efficient and safer approach to anemia management than currently offered by today's intravenous therapies."
So while the stock might be too hot and risky for average investors, biotech-savvy Fools might want to take a closer look at Keryx's brightened prospects.
More reliable ways to build wealth
Dividend stocks can make you rich. It's as simple as that. While they don't garner the notoriety of high-flying growth stocks, they're also less likely to crash and burn. And over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.
The article Why Keryx Shares Skyrocketed originally appeared on Fool.com.
Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
